These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 6242478)
21. An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH. Hierowski MT; Schally AV Horm Res; 1985; 21(2):124-35. PubMed ID: 3156799 [TBL] [Abstract][Full Text] [Related]
22. [Decapeptyl (D-Trp6-LH-RH) in the therapy of prostatic cancer with reference to the intramuscular administration of a depot preparation]. Seppelt U; Bertermann H; Saerbeck C Urologe A; 1986 Sep; 25(5):298-301. PubMed ID: 2947371 [TBL] [Abstract][Full Text] [Related]
23. Endogenous phosphorylation in Dunning prostate tumors of rats treated with LH-RH analogues. Cehovic G; Redding TW; Hierowski MT; Schally AV Prostate; 1984; 5(6):605-11. PubMed ID: 6238290 [TBL] [Abstract][Full Text] [Related]
24. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen. St Arnaud R; Lachance R; Dupont A; Labrie F J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618 [TBL] [Abstract][Full Text] [Related]
25. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. Lamharzi N; Halmos G; Jungwirth A; Schally AV Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774 [TBL] [Abstract][Full Text] [Related]
26. Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations. Mason-Garcia M; Vigh S; Comaru-Schally AM; Redding TW; Somogyvari-Vigh A; Horvath J; Schally AV Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1547-51. PubMed ID: 3156381 [TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Pinski J; Reile H; Halmos G; Groot K; Schally AV Int J Cancer; 1994 Oct; 59(1):51-5. PubMed ID: 7927904 [TBL] [Abstract][Full Text] [Related]
28. LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade. Jacobi GH Recent Results Cancer Res; 1990; 118():174-85. PubMed ID: 2146724 [No Abstract] [Full Text] [Related]
29. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model. Redding TW; Schally AV Prostate; 1985; 6(3):219-32. PubMed ID: 3157927 [TBL] [Abstract][Full Text] [Related]
30. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin. Kadar T; Redding TW; Ben-David M; Schally AV Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378 [TBL] [Abstract][Full Text] [Related]
31. Metastatic carcinoma of the prostate in both testes of patients treated with LH-RH analogues. Hadjissotiriou GG; Papadopoulos S; Rebelakos A Br J Urol; 1992 Jun; 69(6):657-9. PubMed ID: 1386273 [No Abstract] [Full Text] [Related]
32. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. Labrie F; Dupont A; Belanger A; Lachance R J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. Redding TW; Schally AV Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395 [TBL] [Abstract][Full Text] [Related]
34. Prostatic carcinoma with lung metastases in a former bagasse worker; LH-RH analogs as an alternative therapy. Comaru-Schally AM; Kushner DS Am J Med Sci; 1988 Nov; 296(5):348-53. PubMed ID: 2973752 [No Abstract] [Full Text] [Related]
35. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix. Halmos G; Schally AV; Kahan Z Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally AM; Schally AV Breast Cancer Res Treat; 1992; 21(1):35-45. PubMed ID: 1391973 [TBL] [Abstract][Full Text] [Related]
37. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223 [TBL] [Abstract][Full Text] [Related]
38. D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons. Lewis RW; Dowling KJ; Schally AV Proc Natl Acad Sci U S A; 1985 May; 82(9):2975-9. PubMed ID: 3157995 [TBL] [Abstract][Full Text] [Related]
39. [Treatment of precocious puberty with an LH-RH agonist (D-TRP6-LH-RH delayed-release microcapsules)]. Canlorbe P; Chaussain JL; Lahlou N; Roger M; Toublanc JE; Job JC Bull Acad Natl Med; 1988 Nov; 172(8):1091-8. PubMed ID: 2977732 [No Abstract] [Full Text] [Related]